Showing results (621-630 of 6,776) with videos related to

Sort By:
Pageof 678
European Journal of Endocrinology|February 7, 2004
Influence of short-term dietary weight loss on cortisol secretion and metabolism in obese menAlexandra M Johnstone, Peter Faber, Ruth Andrew, et al.
European Journal of Endocrinology|February 7, 2004
Metabolic and endocrine effects of treatment with peroral or transdermal oestrogens in conjunction with peroral cyproterone acetate in women with polycystic ovary syndromeJ Vrbíková, S Stanická, K Dvoráková, et al.
European Journal of Endocrinology|August 7, 2004
Type 2 diabetes and impaired glucose tolerance in European children and adolescents with obesity -- a problem that is no longer restricted to minority groupsSusanna Wiegand, Ursula Maikowski, Oliver Blankenstein, et al.
European Journal of Endocrinology|August 7, 2004
Plasma chromogranin A in incidental non-functioning, benign, solid adrenocortical tumorsGiampaolo Bernini, Angelica Moretti, Vincenzo Fontana, et al.
European Journal of Endocrinology|August 7, 2004
Follistatin-related gene expression, but not follistatin expression, is decreased in human endometrial adenocarcinomaPasquapina Ciarmela, Pasquale Florio, Matthildur Sigurdardottir, et al.
European Journal of Endocrinology|September 15, 2004
Would wider screening for primary aldosteronism give any health benefits?Pierre-Francois Plouin, Xavier Jeunemaitre
European Journal of Endocrinology|September 15, 2004
Adult GH deficiency in Japanese patients: effects of GH treatment in a randomised, placebo-controlled trialKazuo Chihara, Ekaterina Koledova, Akira Shimatsu, et al.
European Journal of Endocrinology|September 15, 2004
RGS 2 expression is regulated by TSH and inhibits TSH receptor signalingMarkus Eszlinger, Hans-Peter Holzapfel, Carsten Voigt, et al.
European Journal of Endocrinology|July 14, 2004
Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumoursGregory Kaltsas, Andrea Rockall, Dimitrios Papadogias, et al.
European Journal of Endocrinology|July 14, 2004
Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptorCarsten Gründker, Lars Schlotawa, Volker Viereck, et al.
Pageof 678